In conclusion, the utilization of the biomarker, aberrant BRCA1 promoter methylation, for early detection of PCa patients may prove beneficial for clinicians in adapting treatment strategies to enhance patient survival. This evidence concerns the gene BRCA1 and posterior cortical atrophy.